Cardiovascular Toxicities of Immune Therapies for Cancer – A Scientific Statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology
Carlo G. Tocchetti(Federico II University Hospital), Alexander R. Lyon(Royal Brompton Hospital), Teresa López‐Fernández(Hospital Universitario La Paz), Liam S. Couch(The Task Force for Global Health), Javid J. Moslehi(Cardiovascular Institute of the South), Christine Brezden‐Masley(Mount Sinai Hospital), Daniela Cardinale(European Institute of Oncology), Pietro Ameri(Ospedale Policlinico San Martino), Ana Barac(Inova Fairfax Hospital), Rudolf A. de Boer(Erasmus MC), Ciro Santoro(Federico II University Hospital), Mariana Mirabel, Chris Plummer(Newcastle upon Tyne Hospitals NHS Foundation Trust), Daniel J. Lenihan(Saint Francis Medical Center), Susan Dent(Government of the United States of America), María Sol Andrés(Royal Brompton Hospital), Christoph Maack(Universitätsklinikum Würzburg), Amam Mbakwem(University of Lagos), Luigi Formisano(University of Naples Federico II), Andrew J.S. Coats(The Heart Research Institute), Aaron L. Sverdlov(Hunter New England Local Health District), Jeroen J. Bax(Leiden University), Marco Metra(Vita-Salute San Raffaele University), Fabrizio Pane(Federico II University Hospital), Michael G. Fradley(University of South Florida), Sivatharshini Ramalingam(Royal Brompton & Harefield NHS Foundation Trust), Dimitrios Farmakis(National and Kapodistrian University of Athens), Lewis Au(Royal Marsden NHS Foundation Trust), Max Emmerich(St Thomas' Hospital), Esther Lutgens(Mayo Clinic), Tienush Rassaf(West German Heart and Vascular Center Essen), Riccardo Asteggiano(University of Insubria), Paaladinesh Thavendiranathan(University of Toronto), Jutta Bergler‐Klein, Petar Seferović, Alain Cohen‐Solal(Inserm), Bonnie Ky(Virginia Commonwealth University), Emilio Hirsch(University of Turin), Hadi Skouri(University of Balamand), Tomas G. Neilan(Albert Einstein College of Medicine), Kalliopi Keramida(National and Kapodistrian University of Athens), Geeta Gulati(Oslo University Hospital), Gilles W. De Keulenaer(University of Antwerp), Joerg Herrmann(Mayo Clinic), Fortunato Ciardiello(University of Campania "Luigi Vanvitelli"), Thomas Suter(University of Bern), Peter van der Meer(University Medical Center Groningen), Giuseppe Rosano(Università degli studi di Cassino e del Lazio Meridionale), Yvonne Koop(University Medical Center Utrecht), Zaza Iakobishvili(Ben-Gurion University of the Negev)
Cited by 64
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k
Guidelines on the management of valvular heart disease (version 2012)
|European Heart Journal|2012|3.6k